Univercell Biosolutions Overview
- Year Founded
-
2010
- Status
-
Out of Business
- Employees
-
11
- Latest Deal Type
-
Out of Business
Univercell Biosolutions General Information
Description
Developer of human stem cells, cellular reprogramming and differentiation technologies designed to accelerate drug discovery and development with more informative and innovative human cell models. The company's technologies offer collaborations with relevant and robust human-induced pluripotent stem cells tailored to fit with most differentiation protocols, enabling customers and medical care professionals to get access to well-characterized and standardized human-induced pluripotent stem cells (hiPSc).
Contact Information
Website
www.univercell-biosolutions.comCorporate Office
- 1 Place Pierre Potier
- Canceropole, Entree B
- 31106 Toulouse Cedex
- France
Corporate Office
- 1 Place Pierre Potier
- Canceropole, Entree B
- 31106 Toulouse Cedex
- France
Univercell Biosolutions Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 14-Jul-2021 | Completed | Out of Business | |||
| 3. Later Stage VC | Completed | Generating Revenue | ||||
| 2. Grant | 31-Jan-2017 | $53.2K | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Univercell Biosolutions Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Univercell Biosolutions Patents
Univercell Biosolutions Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2594635-A1 | Method for generating primate cardiovascular progenitor cells for clinical and drug cells testing use from primate embryonic stem cells or embryonic-like state cells, and their applications | Inactive | 18-Nov-2011 | ||
| US-20140302155-A1 | Production of a human beta cell line from an early post natal pancreas | Active | 18-Oct-2011 | ||
| US-9493743-B2 | Production of a human beta cell line from an early post natal pancreas | Active | 18-Oct-2011 | ||
| ES-2634457-T3 | Production of a human beta cell line from an early postnatal pancreas | Active | 18-Oct-2011 | ||
| EP-2768948-B1 | Production of a human beta cell line from an early post natal pancreas | Active | 18-Oct-2011 | A01K67/0271 |
Univercell Biosolutions Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Univercell Biosolutions Acquisitions (1)
Univercell Biosolutions’s most recent deal was a Merger/Acquisition with EndoCells. The deal was made on 01-Dec-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| EndoCells | 01-Dec-2015 | Merger/Acquisition | Biotechnology |
Univercell Biosolutions FAQs
-
When was Univercell Biosolutions founded?
Univercell Biosolutions was founded in 2010.
-
Where is Univercell Biosolutions headquartered?
Univercell Biosolutions is headquartered in Toulouse Cedex, France.
-
What is the size of Univercell Biosolutions?
Univercell Biosolutions has 11 total employees.
-
What industry is Univercell Biosolutions in?
Univercell Biosolutions’s primary industry is Biotechnology.
-
Is Univercell Biosolutions a private or public company?
Univercell Biosolutions is a Private company.
-
What is Univercell Biosolutions’s current revenue?
The current revenue for Univercell Biosolutions is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
